rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

INSM - Insmed - Deel 15

2.002 Posts
Pagina: «« 1 ... 30 31 32 33 34 ... 101 »» | Laatste | Omlaag ↓
  1. [verwijderd] 22 juni 2007 17:15

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    crackedtooth schreef:

    [quote=Compugreen]
    [quote=gismo74]
    Niet er hoopvol deze informatie m.b.t. ALS.

    investorshub.com/boards/read_msg.asp?...

    [/quote]

    heel onhoopvol
    trouwens, over welke trial hebben ze het daar?
    [/quote]

    vind het erg meevallen, komt erop neer dat hij geen echt nieuws gevonden heeft anders dan wat korte postings op forums... maw hij weet het gewoon niet maar is sceptisch, zet wat vraagtekens zet bij bruno zelf...
    Wat mij vooral verbaasd is dat hij zijn eigen naam met titel gebruikt bij het posten van informatie op dit forum. In hoeverre zijn wij er zeker van dat hij is wie hij zegt?

    www.als.net/forum/topic.asp?TOPIC_ID=...
  3. [verwijderd] 22 juni 2007 18:20

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    IGFBP3 - Ovarian Cancer Invasion Suppressor (8 Ratings) 22-Jun-07 09:12 am

    www.clinicaltrials.gov/ct/show/NCT001...

    "study the relationship among IGFBP-3, metalloproteinase-2 (our previous studies which verified its relationship with tumor invasiveness) and insulin-like growth factor (IGF)-1. We would study the changes in cytoskeletal structures and the known functions of anti-proliferation and apoptosis in IGFBP-3. Furthermore, we would like to investigate the mechanism of IGFBP-3 in the inhibition of invasion/migration of ovarian carcinoma, either signaling through MAPK or PI3K/AKT pathways. Finally, through xenograft, we plan to study for the possible application of IGFBP-3 in ovarian cancer therapy."

    The last patient was enrolled January 2006. The data is now being analyzed and the plan is to release the results next month.

    bwd

    ------------------------

    as posted
    Thank you Biowatchdog
  6. [verwijderd] 22 juni 2007 21:17

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0


    maw hij heeft zijn holdings met 16% uitgebreid naar 1,16 miljoen aandelen

    Weet hij iets meer, hij heeft toch moeten getuigen om generische middelen er door te krijgen.

    Dit te lezen geeft me toch weer moed

  12. ludwig mack 22 juni 2007 22:27

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    After Hours: 0.74 0.02 (2.78%) as of 4:03PM ET on 06/22/07

    Last Trade: 0.72
    Trade Time: 4:00PM ET
    Change: 0.00 (0.00%)
    Prev Close: 0.72
    Open: 0.71
    Bid: 0.71 x 2000
    Ask: 0.75 x 2000
    1y Target Est: 2.00

    Day's Range: 0.71 - 0.77
    52wk Range: 0.68 - 1.98
    Volume: 1,582,052
    Avg Vol (3m): 1,895,740
    Market Cap: 72.96M
    P/E (ttm): N/A
    EPS (ttm): -0.53
    Div & Yield: N/A (N/A)


    nabeurs plus 2 ct, vraag blijft ......
  16. [verwijderd] 25 juni 2007 15:26

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Experienced Biopharmaceutical Executive Steve Glover Joins Insmed; Will Lead Development of Follow-on Biologics

    Last update: 6/25/2007 9:00:43 AM
    RICHMOND, Va., Jun 25, 2007 (BUSINESS WIRE) -- Insmed Inc. (INSM) today announced that Steve Glover, 48, has joined Insmed's management team as President of the newly formed Follow-on Biologics business, effective June 22, 2007. Mr. Glover will be responsible for leading the development of Insmed's follow-on biologics capability and its emerging portfolio of biogeneric/biosimilar products. Mr. Glover brings nearly 25 years of business experience in bio-pharmaceuticals and life sciences to his new position. Prior to joining Insmed, he held the position of Senior Vice President and General Manager at Andrx Laboratories and Andrx Therapeutics, both divisions of Andrx Corporation. He earlier held multiple sales, marketing and operational roles at Hoffman LaRoche, Amgen Inc. and IMS Health. His strategic and operational experience, which covers most therapeutic classes of biopharmaceuticals, includes strategic planning, corporate development, operations management, product development, product marketing and sales management. Mr. Glover commented, "I am excited to join the talented management team that Insmed has assembled -- a team able to leverage Insmed's advanced knowledge of biologics development, its manufacturing capability, and its skilled scientific and technical workforce to make it the first U.S.-based biotechnology company to develop a comprehensive portfolio of follow-on biologics. This is an organization that knows the drug industry is on the threshold of its second generic revolution." Dr. Geoffrey Allan, President and Chief Executive Officer of Insmed, commented, "We are looking forward to benefiting from Steve's extensive leadership experience in the bio-pharmaceutical and life sciences sectors. His expertise will be instrumental in providing the strategic direction and tactical capability to take full advantage of our unique combination of protein know-how and drug approval skills. He will play a pivotal role in our follow-on biologics strategy, which together with the development of our approved flagship product IPLEX(TM) in niche markets, forms a dual-path approach for success."
  18. [verwijderd] 25 juni 2007 18:11

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Insmed: Follow-On Biologics Pres To Get $300,000 Salary/Yr
    Last update: 6/25/2007 12:05:39 PM(MORE TO FOLLOW) Dow Jones NewswiresJune 25, 2007 12:05 ET (16:05 GMT)
  19. [verwijderd] 25 juni 2007 18:17

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Dirk R. Wijnen schreef:

    Insmed: Follow-On Biologics Pres To Get $300,000 Salary/Yr
    Last update: 6/25/2007 12:05:39 PM(MORE TO FOLLOW) Dow Jones NewswiresJune 25, 2007 12:05 ET (16:05 GMT)
    welke newsfeed krijg jij die?
    of via broker?
  20. [verwijderd] 25 juni 2007 18:56

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0


    Form 8-K for INSMED INC

    25-Jun-2007

    Change in Directors or Principal Officers, Financial Statements and Exhibits

    Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
    Effective June 22, 2007, Insmed Incorporated ("Insmed," "our," "we," "us") appointed Steve Glover, age 48, as President of Follow-on Biologics. Since January 2006, Mr. Glover was President and CEO of ZyVer & Associates, a biopharmaceutical consulting firm, through which he has been working as a consultant to us on our follow-on biologics program since March 26, 2007. From March 2003 to December 2006, Mr. Glover served as Senior Vice President and General Manager of Andrx Therapeutics and Andrx Laboratories, both divisions of Andrx Corporation. From January 2001 to February 2003, Mr. Glover served as Founder of Triangular Health Inc., a privately held venture funded company. Mr. Glover received his Bachelor of Science degree in Marketing/Management from Illinois State University.

    In connection with the commencement of his employment, Mr. Glover will be granted an option to purchase up to 250,000 shares of our common stock. The exercise price for the stock subject to his option grant will be the fair market value of our common stock on the date of the option grant which is June 22, 2007. This stock option will become exercisable in four equal annual installments beginning on June 22, 2008, and will be fully exercisable on June 22, 2011. All vesting is contingent on Mr. Glover's continuous employment with us. The stock option will expire on June 22, 2017. Mr. Glover will receive an annual base salary of $300,000 and will be eligible for a discretionary bonus up to 35% of his annual salary.

    We will enter into a change of control agreement with Mr. Glover, which provides for additional benefits in the event that his employment with us is terminated following a change in control of Insmed. The form of change of control agreement to be entered into between us and Mr. Glover was previously filed as Exhibit 10.21 to our Annual Report on Form 10-K for the year ended December 31, 2006 and is herein incorporated by reference. There are no related party transactions between us and Mr. Glover. A copy of the Press Release announcing that Mr. Glover has joined Insmed is attached hereto as Exhibit 99.1.

    Item 9.01. Financial Statements and Exhibits

2.002 Posts
Pagina: «« 1 ... 30 31 32 33 34 ... 101 »» | Laatste |Omhoog ↑

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.012
AB InBev 2 5.495
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.540
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.588
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.732
Aedifica 3 903
Aegon 3.258 322.687
AFC Ajax 538 7.087
Affimed NV 2 6.289
ageas 5.844 109.887
Agfa-Gevaert 14 2.049
Ahold 3.538 74.331
Air France - KLM 1.025 35.024
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.698
Allfunds Group 4 1.469
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.819
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.836 242.934
AMG 971 133.207
AMS 3 73
Amsterdam Commodities 305 6.687
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 14.975
Apollo Alternative Assets 1 17
Apple 5 381
Arcadis 252 8.767
Arcelor Mittal 2.033 320.663
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.296
Aroundtown SA 1 219
Arrowhead Research 5 9.730
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.089
ASML 1.766 106.504
ASR Nederland 21 4.452
ATAI Life Sciences 1 7
Atenor Group 1 485
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.647
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392